Leading pharmaceutical firms eye N&A as growth engine

Published: 2010-03-31 06:58:00

Updated: 2010-03-31 06:58:00

Large domestic enterprises are eyeing mergers and acquisitions (M&As) with a promising pharmaceutical bulk manufacturer as part of efforts to find new growth engines in the rapidly changing business environment.

Korean pharmaceutical manufactuers have remained cautious and passive toward M&As ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK